Skeletal muscle mass during chemotherapy for haematological malignancies: a retrospective study.
Mamiko TakahashiShin KondoKumiko KagawaMasafumi NakamuraYusaku MaedaRyohei SumitaniHikaru YagiMasahiro OuraKimiko SogabeTakeshi HaradaShiro FujiiHirokazu MikiItsuro EndoMasahiro AbeShingen NakamuraPublished in: BMJ supportive & palliative care (2024)
Muscle loss occurred following anticancer treatments, significantly contributing to worse outcomes. Body composition assessment and relevant multimodal prevention of muscle loss may be vital for patients receiving chemotherapy for haematological malignancies.